Question 1

What is Adalimumab-Atto used for?

Accepted Answer

Adalimumab-Atto suppresses inflammation by blocking tumor necrosis factor, used in autoimmune conditions.

Question 2

Is there a generic for Adalimumab-Atto?

Accepted Answer

No. Adalimumab-Atto is brand-only with no generic equivalents currently in market.

Question 3

How much does my plan pay for Adalimumab-Atto?

Accepted Answer

NADAC pricing data not currently available for this drug.

Question 4

Is Adalimumab-Atto on the FDA shortage list?

Accepted Answer

No. Adalimumab-Atto is not currently on the FDA Drug Shortage Database.

Question 5

What drug class is Adalimumab-Atto in?

Accepted Answer

Adalimumab-Atto is in the Tumor Necrosis Factor Blocker class. See related drugs in this class at /class/tumor-necrosis-factor-blocker.

Question 6

What is the brand name for Adalimumab-Atto?

Accepted Answer

Adalimumab-Atto is sold under the brand name AMJEVITA.

Question 7

Is AMJEVITA the same as Adalimumab-Atto?

Accepted Answer

Yes. AMJEVITA is a brand name for Adalimumab-Atto. The generic version is identical in active ingredient, dose, and FDA-approved indications. Pricing differs substantially: generic Adalimumab-Atto typically prices well below brand AMJEVITA.

Question 8

How much does Medicare spend on Adalimumab-Atto per year?

Accepted Answer

Medicare Part D spent $64.2M on Adalimumab-Atto in CY2024, across 44K prescriptions and 10K unique beneficiaries.

Question 9

Why is Adalimumab-Atto on Tier 3 across most plans?

Accepted Answer

Adalimumab-Atto appears on Tier 3 in 10 plan-NDC pairs and Tier 1 in only 0. The reason is structural: PBM rebate guarantees on brand-tier placement reduce the PBM's incentive to move the molecule to a lower tier even when generic competition exists. Moving to Tier 1 is typically possible only at plan-year reset or via contract renegotiation.

Question 10

What can I switch to instead of Adalimumab-Atto?

Accepted Answer

Same-class alternatives include: Adalimumab-Adaz, Adalimumab-Aqvh, Adalimumab-Bwwd. Whether substitution is clinically appropriate depends on patient indication, dose schedule, and contraindications — that is a P&T committee decision. The federal data shows cost and competition; clinical equivalence is not asserted here.

Question 11

When was Adalimumab-Atto first FDA approved?

Accepted Answer

Adalimumab-Atto received its first FDA approval on 2023-01-31.

Adalimumab-Atto (AMJEVITA)

$64.2M in CY2024 Part D spend44K claims · 10K beneficiaries · 329 plans surveyed

Questions a plan sponsor actually asks.

Related questions.

Same class. Different math.

Sources · every number above traces back.